JP2021517457A5 - - Google Patents

Download PDF

Info

Publication number
JP2021517457A5
JP2021517457A5 JP2020548645A JP2020548645A JP2021517457A5 JP 2021517457 A5 JP2021517457 A5 JP 2021517457A5 JP 2020548645 A JP2020548645 A JP 2020548645A JP 2020548645 A JP2020548645 A JP 2020548645A JP 2021517457 A5 JP2021517457 A5 JP 2021517457A5
Authority
JP
Japan
Prior art keywords
seq
region
amino acid
heavy chain
light chain
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020548645A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021517457A (ja
JP7209008B2 (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2019/056197 external-priority patent/WO2019175198A2/en
Publication of JP2021517457A publication Critical patent/JP2021517457A/ja
Publication of JP2021517457A5 publication Critical patent/JP2021517457A5/ja
Priority to JP2022143428A priority Critical patent/JP7447208B2/ja
Application granted granted Critical
Publication of JP7209008B2 publication Critical patent/JP7209008B2/ja
Priority to JP2024027970A priority patent/JP7791229B2/ja
Priority to JP2025245068A priority patent/JP2026041981A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020548645A 2018-03-12 2019-03-12 抗体 Active JP7209008B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022143428A JP7447208B2 (ja) 2018-03-12 2022-09-09 抗体
JP2024027970A JP7791229B2 (ja) 2018-03-12 2024-02-28 抗体
JP2025245068A JP2026041981A (ja) 2018-03-12 2025-12-11 抗体

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP18161293.8 2018-03-12
EP18161293 2018-03-12
EP18175347 2018-05-31
EP18175347.6 2018-05-31
PCT/EP2019/056197 WO2019175198A2 (en) 2018-03-12 2019-03-12 Antibodies

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022143428A Division JP7447208B2 (ja) 2018-03-12 2022-09-09 抗体

Publications (3)

Publication Number Publication Date
JP2021517457A JP2021517457A (ja) 2021-07-26
JP2021517457A5 true JP2021517457A5 (https=) 2021-10-07
JP7209008B2 JP7209008B2 (ja) 2023-01-19

Family

ID=65729373

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2020548645A Active JP7209008B2 (ja) 2018-03-12 2019-03-12 抗体
JP2022143428A Active JP7447208B2 (ja) 2018-03-12 2022-09-09 抗体
JP2024027970A Active JP7791229B2 (ja) 2018-03-12 2024-02-28 抗体
JP2025245068A Pending JP2026041981A (ja) 2018-03-12 2025-12-11 抗体

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022143428A Active JP7447208B2 (ja) 2018-03-12 2022-09-09 抗体
JP2024027970A Active JP7791229B2 (ja) 2018-03-12 2024-02-28 抗体
JP2025245068A Pending JP2026041981A (ja) 2018-03-12 2025-12-11 抗体

Country Status (20)

Country Link
US (5) US20200277397A1 (https=)
EP (1) EP3765493A2 (https=)
JP (4) JP7209008B2 (https=)
KR (1) KR20200130723A (https=)
CN (2) CN120795158A (https=)
AU (2) AU2019233523B2 (https=)
BR (1) BR112020018490A2 (https=)
CA (1) CA3093745A1 (https=)
CL (1) CL2020002326A1 (https=)
CO (1) CO2020012524A2 (https=)
CR (3) CR20200463A (https=)
EC (1) ECSP20063690A (https=)
IL (1) IL277030A (https=)
MA (1) MA52152A (https=)
MX (7) MX2020009379A (https=)
PE (1) PE20210339A1 (https=)
PH (1) PH12020551447A1 (https=)
SA (3) SA520420109B1 (https=)
SG (1) SG11202008399QA (https=)
WO (1) WO2019175198A2 (https=)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL319047A (en) 2015-08-28 2025-04-01 Amunix Operating Inc Chimeric polypeptide composition and methods for its preparation and use
SG11202008399QA (en) 2018-03-12 2020-09-29 Genmab As Antibodies
WO2021048423A1 (en) * 2019-09-12 2021-03-18 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer
US20230390424A1 (en) * 2020-09-11 2023-12-07 Actinium Pharmaceuticals, Inc. Trophoblast glycoprotein radioimmunotherapy for the treatment of solid cancers
AU2022214319A1 (en) 2021-01-28 2023-08-03 Regeneron Pharmaceuticals, Inc. Compositions and methods for treating cytokine release syndrome
MX2023013018A (es) * 2021-05-04 2024-01-18 Immunorizon Ltd Anticuerpos anti-5t4 y usos de estos.
US20230220106A1 (en) * 2021-12-08 2023-07-13 Dragonfly Therapeutics, Inc. Antibodies targeting 5t4 and uses thereof
EP4507790A1 (en) 2022-04-11 2025-02-19 Regeneron Pharmaceuticals, Inc. Compositions and methods for universal tumor cell killing
JP2025537193A (ja) * 2022-11-08 2025-11-14 フェインズ セラピューティクス，インコーポレーテッド 抗５ｔ４抗体及びその使用
CN120857940A (zh) 2023-02-17 2025-10-28 瑞泽恩制药公司 对cd3/taa双特异性抗体有反应的诱导型nk细胞

Family Cites Families (63)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4699880A (en) 1984-09-25 1987-10-13 Immunomedics, Inc. Method of producing monoclonal anti-idiotype antibody
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
GB9203459D0 (en) 1992-02-19 1992-04-08 Scotgen Ltd Antibodies with germ-line variable regions
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
ATE299938T1 (de) 1997-05-02 2005-08-15 Genentech Inc Ein verfahren zur herstellung multispezifischer antikörper die heteromultimere und gemeinsame komponenten besitzen
US6852703B1 (en) 1997-06-04 2005-02-08 Oxford Biomedica (Uk) Limited Tumor targeted vector
WO2000046147A2 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
JP2003515323A (ja) 1999-11-18 2003-05-07 オックスフォード バイオメディカ（ユーケイ）リミテッド 抗 体
DE10043437A1 (de) 2000-09-04 2002-03-28 Horst Lindhofer Verwendung von trifunktionellen bispezifischen und trispezifischen Antikörpern zur Behandlung von malignem Aszites
GB0126378D0 (en) 2001-11-02 2002-01-02 Oxford Biomedica Ltd Antigen
DK2314629T4 (da) 2002-07-18 2023-02-06 Merus Nv Rekombinant produktion af blandinger af antistoffer
SV2007002227A (es) 2004-09-10 2007-03-20 Wyeth Corp Anticuerpos anti-5t4 humanizados y conjugados anticuerpo anti-5t4/calicheamicina ref. 040000-0317637
US7741568B2 (en) 2005-01-13 2010-06-22 The Wiremold Company Downward facing receptacle assembly for cable raceway
AU2006232287B2 (en) 2005-03-31 2011-10-06 Chugai Seiyaku Kabushiki Kaisha Methods for producing polypeptides by regulating polypeptide association
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
CA2631184A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
DK2368914T3 (en) 2006-03-10 2019-03-04 Wyeth Llc Anti-5T4 antibodies and uses thereof
CA2646508A1 (en) 2006-03-17 2007-09-27 Biogen Idec Ma Inc. Stabilized polypeptide compositions
PT1999154E (pt) 2006-03-24 2013-01-24 Merck Patent Gmbh Domínios proteicos heterodiméricos modificados
AT503902B1 (de) 2006-07-05 2008-06-15 F Star Biotech Forsch & Entw Verfahren zur manipulation von immunglobulinen
ES2593484T3 (es) 2007-03-29 2016-12-09 Genmab A/S Anticuerpos biespecíficos y métodos de producción de los mismos
EP2158221B1 (en) 2007-06-21 2018-08-29 MacroGenics, Inc. Covalent diabodies and uses thereof
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
JP6157046B2 (ja) 2008-01-07 2017-07-05 アムジェン インコーポレイテッド 静電的ステアリング（ｅｌｅｃｔｒｏｓｔａｔｉｃｓｔｅｅｒｉｎｇ）効果を用いた抗体Ｆｃヘテロ二量体分子を作製するための方法
WO2010015792A1 (en) 2008-08-06 2010-02-11 Argenta Discovery Limited Nitrogen containing heterocyclic compounds useful as bifunctional modulators of m3 receptors and beta-2 receptors
JP5397668B2 (ja) 2008-09-02 2014-01-22 ソニー株式会社 記憶素子および記憶装置
DK2786762T3 (da) 2008-12-19 2019-05-06 Macrogenics Inc Kovalente diabodies og anvendelser deraf
WO2010129304A2 (en) 2009-04-27 2010-11-11 Oncomed Pharmaceuticals, Inc. Method for making heteromultimeric molecules
WO2011028952A1 (en) 2009-09-02 2011-03-10 Xencor, Inc. Compositions and methods for simultaneous bivalent and monovalent co-engagement of antigens
GB0918383D0 (en) 2009-10-20 2009-12-02 Cancer Rec Tech Ltd Prognostic,screening and treatment methods and agents for treatment of metastasis and inflammation
AR080794A1 (es) 2010-03-26 2012-05-09 Hoffmann La Roche Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
HRP20241208T1 (hr) 2010-04-20 2024-11-22 Genmab A/S Heterodimerni proteini koji sadrže fc fragment protutijela i postupci za njihovu proizvodnju
US9527926B2 (en) 2010-05-14 2016-12-27 Rinat Neuroscience Corp. Heterodimeric proteins and methods for producing and purifying them
EP2576621B1 (en) 2010-05-27 2019-04-10 Genmab A/S Monoclonal antibodies against her2
CN103068847B (zh) 2010-08-24 2019-05-07 罗切格利卡特公司 可活化的双特异性抗体
CN103068846B9 (zh) 2010-08-24 2016-09-28 弗·哈夫曼-拉罗切有限公司 包含二硫键稳定性Fv片段的双特异性抗体
ES2758994T3 (es) 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
CN102250246A (zh) 2011-06-10 2011-11-23 常州亚当生物技术有限公司 抗VEGF/PDGFRβ双特异性抗体及其应用
CA2846432A1 (en) * 2011-09-23 2013-03-28 Amgen Research (Munich) Gmbh Bispecific binding molecules for 5t4 and cd3
SG11201401422VA (en) 2011-10-27 2014-09-26 Genmab As Production of heterodimeric proteins
CN104736174B (zh) 2012-07-06 2019-06-14 根马布私人有限公司 具有三重突变的二聚体蛋白质
WO2014137931A1 (en) 2013-03-06 2014-09-12 Imaginab, Inc. Antigen binding constructs to 5t4
ME03675B (me) 2013-07-05 2020-10-20 Genmab As Humanizovana ili himerna anтi-cd3 antiтela
WO2015155345A1 (en) * 2014-04-11 2015-10-15 Medimmune Limited Antibodies and antibody-drug conjugates
WO2016022939A1 (en) * 2014-08-08 2016-02-11 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Human monoclonal antibodies specific for 5t4 and methods of their use
MX384198B (es) * 2014-12-19 2025-03-14 Chiome Bioscience Inc Proteina de fusion que comprende tres dominios de union a 5t4 y cd3.
IL256562B2 (en) 2015-07-15 2024-07-01 Genmab As Human CD3 antibodies or chimeras
SG11201802698XA (en) 2015-10-29 2018-05-30 Hoffmann La Roche Transgenic rabbit with common light chain
EP3184547A1 (en) * 2015-10-29 2017-06-28 F. Hoffmann-La Roche AG Anti-tpbg antibodies and methods of use
AU2016358854B2 (en) * 2015-11-24 2023-02-02 Byondis B.V. Anti-5T4 antibodies and antibody-drug conjugates
WO2017107973A1 (zh) * 2015-12-24 2017-06-29 凯惠科技发展(上海)有限公司 一种tpbg抗体及其制备方法、其偶联物和应用
EP3445788B1 (en) * 2016-04-22 2022-01-19 Alligator Bioscience AB Novel bispecific polypeptides against cd137
CN108285487B (zh) 2017-01-08 2021-02-19 浙江昭华生物医药有限公司 抗5t4抗体-药物偶联物及其应用
KR20230166145A (ko) 2017-03-15 2023-12-06 옥스포드 바이오메디카(유케이) 리미티드 방법
US11608384B2 (en) 2017-04-05 2023-03-21 Xdcexplorer (Shanghai) Co., Ltd. Humanized anti-TPBG antibody, preparation method therefor, conjugate thereof, and applications
EP3655439A1 (en) 2017-07-20 2020-05-27 Aptevo Research and Development LLC Antigen binding proteins binding to 5t4 and 4-1bb and related compositions and methods
US20220267403A1 (en) 2017-12-01 2022-08-25 Fred Hutchinson Cancer Research Center Binding proteins specific for 5t4 and uses thereof
JP7337079B2 (ja) 2018-02-15 2023-09-01 マクロジェニクス，インコーポレーテッド 変異型ｃｄ３結合ドメイン、及び疾患の治療のための併用療法におけるその使用
SG11202008399QA (en) 2018-03-12 2020-09-29 Genmab As Antibodies
WO2021048423A1 (en) * 2019-09-12 2021-03-18 Genmab A/S Bispecific antibodies binding to 5t4 and cd3 for use in treatment of cancer

Similar Documents

Publication Publication Date Title
JP2021517457A5 (https=)
JP2021534779A (ja) 抗体構築物がプレロードされた凍結保存ｎｋ細胞
JP2020504171A (ja) 抗ＰＤ−１抗体との組み合わせのための抗Ｔｉｍ−３抗体
EP3882276A1 (en) Bispecific antibody, preparation method therefor and application thereof
NZ791623A (en) Anti-CTLA4 and anti-PD-1 bifunctional antibody, pharmaceutical composition thereof and use thereof
WO2020114478A1 (zh) Cd3抗体及其药物用途
JP2018531219A6 (ja) Ｐｄ−ｌ１抗体
JP2018531219A (ja) Ｐｄ−ｌ１抗体
JP2023517753A5 (https=)
WO2020114479A1 (zh) 多特异性蛋白分子
CN114981301B (zh) Pd1和vegfr2双结合剂
JP2023513200A (ja) 抗ｃｄ３および抗ｃｄ１２３二重特異性抗体およびその使用
CN112166125B (zh) 全人源的抗lag-3抗体及其应用
KR20230074192A (ko) 인간 cd3 엡실론에 결합하는 신규의 인간 항체
CN112771075A (zh) 结合至cd33和cd3的双特异性抗体构建体的延长施用
US20230312709A1 (en) Antibody targeting CD47 and application thereof
CN119060184B (zh) 抗rage抗体及其应用
WO2024012434A1 (en) Antibody, antigen-binding fragment thereof, and pharmaceutical use thereof
EP4703384A1 (en) Bispecific antibody targeting g protein-coupled receptor
US20240376208A1 (en) Duplexbodies
CN115368457A (zh) 抗tigit抗体及其用途
Zettlitz et al. Humanization of a mouse monoclonal antibody directed against a cell surface-exposed epitope of membrane-associated heat shock protein 70 (Hsp70)
JP2022547135A (ja) 増強されたプロテインｌ捕捉動的結合容量を有する二重特異性抗原結合ポリペプチドの精製方法
CN119371542B (zh) 抗rage抗体及其应用
JP7844430B2 (ja) 抗ｇｐｒｃ５ｄ抗体に対する抗イディオタイプ抗体